BCG vaccination at three different age groups: response and effectiveness.

BCG vaccination at three different age groups: response and effectiveness.
April 1, 2005
George Briassoulis, Irene Karabatsou, Vasilis Gogoglou, and Athina Tsorva
J Immune Based Ther Vaccines
Medline Abstract
Highire Press
BACKGROUND: The protection, which some BCG vaccines could confer against the development of tuberculosis (TB) in childhood, might be indirectly reflected by the subsequent development of BCG immune response. The objectives of the study were to examine effectiveness and possible differences of post-vaccination reaction to a lyophilized BCG at different age groups and to evaluate its protection against TB in a decades period. METHODS: We studied the post-vaccination PPD-skin reaction and scar formation at three different school levels, corresponding to ages of 6, 12 and 15 years old, vaccinated by a lyophilized BCG vaccine (Pasteur Institute), currently used in our country. During a 10-year follow up the reported TB cases in vaccinated and non-vaccinated adolescences up to 24-years old were analyzed and compared to the number of cumulative cases observed in the adult population of two neighboring territories (vaccinated and non-vaccinated). Results and Discussion There was a significant correlation (r2= 0.87, p<0.0001) between tuberculin induration and scar formation. There was no statistically significant difference between the three age groups (6, 12, and 15 year-old, respectively) in regard to the diameter of tuberculin induration or scar formation. Although 34% of 10-year later indurations were unpredictably related to the initial ones (increased or decreased), they were significantly correlated (r2 =0.45, p=0.009). The relative percentage of TB for the 14-24 years-age group to the adult studied population was significantly lower among the immunized children compared to the non-immunized population of the same age group (17/77, 22% vs. 71/101, 70%, p<.0001). CONCLUSIONS: Our data suggest that the lyophilized BCG vaccine used for BCG programs at different age groups is equally effective and may confer satisfactory protection against tuberculosis in puberty.
PMID: 15804351
Note: This is an abstract. You will find a link to pay for the entire article.